Recombinant human neuregulin-1

重组人纽兰格林

Report date: 2024/06/20 10:32:07
First In Class

Base Information

Drug NameRecombinant human neuregulin-1
Drug Alias NameRecombinant human neuregulin-1 betaRecombinant Human Neuregulin-1βrhNRG-1-betaNeucardin纽卡定 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-4 agonistsReceptor protein-tyrosine kinase erbB-2 agonists
TargetsReceptor protein-tyrosine kinase erbB-4Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMyocardial InfarctionHeart Failure, SystolicHeart Failure, Diastolic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesZensun (Shanghai) Sci&Tech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZensun Sci. & Tech Co LtdZensun (Shanghai) Sci&Tech Co Ltd
Inactive CompaniesShanghai Zesheng Pharmaceutical Co Ltd
Active IndicationsMyocardial InfarctionHeart Failure, SystolicHeart Failure, Diastolic +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A